Codexis, Inc. (NASDAQ:CDXS) Sees Large Increase in Short Interest

Codexis, Inc. (NASDAQ:CDXS) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 4,570,000 shares, an increase of 50.8% from the February 28th total of 3,030,000 shares. Based on an average trading volume of 843,500 shares, the short-interest ratio is currently 5.4 days. Currently, 5.7% of the shares of the company are short sold.

Hedge Funds Weigh In On Codexis

Large investors have recently bought and sold shares of the stock. CenterBook Partners LP bought a new stake in shares of Codexis in the fourth quarter valued at about $4,688,000. Tallon Kerry Patrick bought a new position in Codexis during the fourth quarter valued at about $2,018,000. Vanguard Group Inc. raised its holdings in Codexis by 7.5% in the 4th quarter. Vanguard Group Inc. now owns 4,463,801 shares of the biotechnology company’s stock valued at $21,292,000 after acquiring an additional 311,082 shares in the last quarter. Telemark Asset Management LLC lifted its position in shares of Codexis by 11.3% in the 4th quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company’s stock worth $14,310,000 after acquiring an additional 303,589 shares during the period. Finally, Nuveen Asset Management LLC grew its holdings in shares of Codexis by 18.6% during the 4th quarter. Nuveen Asset Management LLC now owns 1,812,345 shares of the biotechnology company’s stock worth $8,645,000 after purchasing an additional 283,760 shares in the last quarter. 78.54% of the stock is currently owned by institutional investors and hedge funds.

Codexis Stock Down 4.3 %

CDXS stock opened at $2.69 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. The company has a 50-day moving average of $3.67 and a two-hundred day moving average of $3.95. The stock has a market capitalization of $222.83 million, a price-to-earnings ratio of -3.09 and a beta of 2.12. Codexis has a 52-week low of $2.43 and a 52-week high of $6.08.

Codexis (NASDAQ:CDXS) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.09). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The business had revenue of $21.46 million during the quarter, compared to analyst estimates of $27.41 million. As a group, equities research analysts anticipate that Codexis will post -0.77 EPS for the current year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.